Cellectis Past Earnings Performance

Past criteria checks 0/6

Cellectis's earnings have been declining at an average annual rate of -1.3%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 24.5% per year.

Key information

-1.3%

Earnings growth rate

7.2%

EPS growth rate

Biotechs Industry Growth30.8%
Revenue growth rate-24.5%
Return on equity-65.3%
Net Margin-234.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

A Look At The Intrinsic Value Of Cellectis S.A. (EPA:ALCLS)

Feb 07
A Look At The Intrinsic Value Of Cellectis S.A. (EPA:ALCLS)

Analyst Forecasts Just Became More Bearish On Cellectis S.A. (EPA:ALCLS)

Aug 09
Analyst Forecasts Just Became More Bearish On Cellectis S.A. (EPA:ALCLS)

Is Cellectis (EPA:ALCLS) Using Too Much Debt?

Dec 14
Is Cellectis (EPA:ALCLS) Using Too Much Debt?

Analysts' Revenue Estimates For Cellectis S.A. (EPA:ALCLS) Are Surging Higher

Aug 07
Analysts' Revenue Estimates For Cellectis S.A. (EPA:ALCLS) Are Surging Higher

We Think Some Shareholders May Hesitate To Increase Cellectis S.A.'s (EPA:ALCLS) CEO Compensation

May 26
We Think Some Shareholders May Hesitate To Increase Cellectis S.A.'s (EPA:ALCLS) CEO Compensation

Is Cellectis (EPA:ALCLS) Using Debt Sensibly?

May 17
Is Cellectis (EPA:ALCLS) Using Debt Sensibly?

These Analysts Think Cellectis S.A.'s (EPA:ALCLS) Sales Are Under Threat

Mar 08
These Analysts Think Cellectis S.A.'s (EPA:ALCLS) Sales Are Under Threat

Cellectis (EPA:ALCLS) Is In A Strong Position To Grow Its Business

Feb 16
Cellectis (EPA:ALCLS) Is In A Strong Position To Grow Its Business

Revenue & Expenses Breakdown

How Cellectis makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ENXTPA:ALCLS Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2436-841995
30 Jun 2420-791790
31 Mar 2412-781789
31 Dec 239-1091788
30 Sep 2325-921484
30 Jun 2325-971689
31 Mar 2325-911692
31 Dec 2226-911798
30 Sep 22-5-631197
30 Jun 224-7816108
31 Mar 2214-9920113
31 Dec 2139-8623118
30 Sep 2168-12940120
30 Jun 2167-12141106
31 Mar 2159-1134197
31 Dec 2060-372377
30 Sep 2073-794194
30 Jun 2073-664196
31 Mar 2071-674498
31 Dec 1923-1024392
30 Sep 1920-884583
30 Jun 1911-954580
31 Mar 1917-694573
31 Dec 1821-794777
30 Sep 1825-835075
30 Jun 1831-865077
31 Mar 1831-1054977
31 Dec 1734-994579
30 Sep 1740-864479
30 Jun 1745-744274
31 Mar 1757-564278
31 Dec 1656-674378
30 Sep 1676-454076
30 Jun 1674-453879
31 Mar 1665-643773
31 Dec 1563-233058
30 Sep 1539-282544
30 Jun 1537-102130
31 Mar 1533121719
31 Dec 143231617
30 Sep 1428-81619
30 Jun 1424-211822
31 Mar 1421-292123
31 Dec 1318-362425

Quality Earnings: ALCLS is currently unprofitable.

Growing Profit Margin: ALCLS is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ALCLS is unprofitable, and losses have increased over the past 5 years at a rate of 1.3% per year.

Accelerating Growth: Unable to compare ALCLS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALCLS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: ALCLS has a negative Return on Equity (-65.27%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 05:48
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cellectis S.A. is covered by 21 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Madhu KumarBaird
Huidong WangBarclays